StockData
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.47−0.05 (-3.29%)

Close on Nov 13, 2026Market cap $84.46MP/E –Yield –

Black Diamond Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Black Diamond Therapeutics's price to sales ratio was 2.2× on Apr 30, 2026.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20262.2×+0.2
2025Dec 31, 20252.0×–

More Black Diamond Therapeutics figures

See a number that looks wrong?